secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2022-08-16T23:59:59+00:00
Accession:  0001683168-22-005782
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte (PMCB) reaches cooperation deal with Iroquois; appoints five new independent directors
--------------------------------------------------------------------------------

- Five prior directors resigned; five new directors appointed to reconstituted 7-member board effective Aug 15, 2022.
- Iroquois, holding ~6.7% stake, gets two appointees (Schechter, Silverman); standstill until Sept 30, 2024 or later.
- New independent directors: Allen, Farb, Stover join existing directors Waggoner and Abecassis.
- New directors receive $12,500/quarter cash retainer, 334 shares, and option for 334 shares with five-year term.
- Iroquois agreed to customary standstill, including voting and ownership limits (14.9% cap) through standstill period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/pharmacyte_8k-081422.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-005782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer